Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 5;117(13):2652–2663. doi: 10.1093/cvr/cvab074

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Therapeutic efficacy of GSK484-loaded Col IV-targeted NPs in a mouse preparation of superficial erosion. Immunohistochemical analysis of previously injured LCCA subjected to flow perturbation from mice (n = 8–12 per group, representative image shown) treated with free GSK484 (GSK) and GSK-loaded into bare NPs (GSK-NPs) and Col IV-NPs (GSK-Col IV-NPs). NPs were injected in PBS as vehicle. CD31 (endothelial cell marker) and H3Cit (citrullinated histone, neutrophil extracellular traps marker) staining revealed a significantly improved therapeutic efficacy for the group treated with GSK-Col IV-NPs as gauged by preservation of endothelial continuity and reduction of NET accumulation downstream of the flow perturbation, as shown by the representative data in the graph. Inserts show higher magnification of H3cit staining. (Scale bar 100 µm). One-Way ANOVA. *P < 0.05; **P < 0.01; ****P < 0.0001.